Table 1.
The efficacy of programmed cell death-1/programmed cell death-1 ligand checkpoint inhibitors for the second-line treatment of advanced squamous cell lung cancer in phase III randomised controlled trials
| RCTs | Setting | Histology | No. of sqclc/Tpts | Agent/dose | Clinical efficacy |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OS |
PFS |
ORR | |||||||||
| Median (months) | HR (sqclc) | 95% CI | Median (months) | HR (sqclc) | 95% CI | ||||||
| CheckMate 017 | Second-line | SQCLC | 135/135 | Nivolumab 3 mg/kg q2w |
9.2 | 0.59 | 0.44 to 0.79 | 3.5 | 0.62 | 0.47 to 0.81 | 20% |
| 137/137 | Docetaxel | 6.0 | / | / | 2.8 | / | / | 9% | |||
| KEYNOTE 010 | Second-line | NSCLC | 76/344 | Pembrolizumab 2 mg/kg q3w |
0.74 | 0.50 to 1.09 | 3.9 | 0.86 | 0.62 to 1.20 | 18% | |
| 80/346 | Pembrolizumab 10 mg/kg q3w |
4.0 | 18% | ||||||||
| 66/343 | Docetaxel | / | 4.0 | / | 9% | ||||||
| OAK | Second-line | NSCLC | 112/425 | Atezolizumab 1200 mg q3w |
8.9 | 0.73 | 0.54 to 0.98 | 2.8 | / | / | |
| 110/425 | Docetaxel | 7.7 | / | / | 4.0 | / | / | ||||
NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; q2w, every 2 weeks; q3w, every 3 weeks; RCTs, randomised controlled trials; SQCLC/sqclc, squamous cell lung cancer; Tpts, total patients.